Bill Text: WV HB2408 | 2019 | Regular Session | Introduced
Bill Title: Requiring hospitals and birthing centers to also test newborn infants for spinal muscular atrophy
Spectrum: Bipartisan Bill
Status: (Introduced - Dead) 2019-01-15 - To House Health and Human Resources [HB2408 Detail]
Download: West_Virginia-2019-HB2408-Introduced.html
WEST virginia legislature
2019 regular session
Introduced
House Bill 2408
By Delegate Byrd
[Introduced January 15, 2019; Referred
to the Committee on Health and Human Resources]
A BILL to amend and reenact §16-22-3 of the Code of West Virginia, 1931, as amended, relating to requiring hospitals and birthing centers to also test newborn infants for spinal muscular atrophy.
Be it enacted by the Legislature of West Virginia:
ARTICLE 22. DETECTION AND CONTROL OF PHENYLKETONURIA, GALACTOSEMIA, HYPOTHYROIDISM, AND CERTAIN OTHER DISEASES IN NEWBORN CHILDREN.
§16-22-3. Tests for diseases specified by the state Public Health Commissioner; reports; assistance to afflicted children; Public Health Commissioner to propose rules.
(a) The hospital or birthing center in which an infant is
born, the parents or legal guardians, the physician attending a newborn child,
or any person attending a newborn child not under the care of a physician shall
require and ensure that each such child be tested for phenylketonuria,
galactosemia, hypothyroidism, sickle cell anemia, and certain other diseases
specified by the Bureau for Public Health. The Bureau for Public Health shall
also require testing for congenital adrenal hyperplasia, cystic fibrosis, and
biotinidase deficiency, No later than July 1, 2008, the Bureau for Public
Health shall also require testing for isovaleric acidemia, glutaric
acidemia type I, 3-Hydroxy-3-methylglutaric aciduria, multiple carboxylase
deficiency, methylmalonic acidemia-mutase deficiency form, 3-methylcrotonyl-CoA
carboxylase deficiency, methylmalonic acidemia, Cbl A and Cbl B forms,
propionic acidemia, beta-ketothiolase deficiency, medium-chain acyl-CoA
dehydrogenase deficiency, very long-chain acyl-CoA dehydrogenase deficiency,
long-chain hydroxyacyl-CoA dehydrogenase deficiency, trifunctional protein
deficiency, carnitine uptake defeat, maple syrup urine disease, homocystinuria,
citrullinemia type I, argininosuccinate acidemia, tyrosinemia type I,
hemoglobin S/Beta-thalassemia, sickle C disease, spinal muscular atrophy
and hearing deficiency, and other diseases as specified by the Bureau
for Public Health.
(b) A positive result on any test specified in §16-22-3(a) of this code, or a positive result for any other diseases specified by the Bureau for Public Health, shall be promptly reported to the Bureau for Public Health by the director of the laboratory performing such test.
(c) Newborn screenings shall be considered a covered benefit reimbursed to the birthing facilities by Public Employees Insurance Agency, the state Children's Health Insurance Program, the Medicaid program and all health insurers whose benefit package includes pregnancy coverage and who are licensed under chapter 33 of this code.
(d) The Bureau for Public Health shall propose rules for legislative approval in accordance with §29-3-1 et seq. of this code. These legislative rules shall include:
(1) A means for the Bureau for Public Health, in
cooperation with other state agencies, and with attending physicians, to
provide medical, dietary and related assistance to children determined to be
afflicted with any disease specified in §16-22-3(a) of this code and certain
other diseases specified by the Bureau for Public Health; and
(2) A means for payment for the screening provided for in this section; and
(3) Anything further considered necessary by the Bureau for Public Health to implement the provisions of this section.
NOTE: The purpose of this bill is to require hospitals and birthing centers to also test newborn infants for spinal muscular atrophy.
Strike-throughs indicate language that would be stricken from a heading or the present law and underscoring indicates new language that would be added.